International joint research with Fudan University of China, published in the world’s most acclaimed journal in the immunotherapy of cancer sector
Proved treatment of primary cancer and removal of cancer metastasis in studies on lab rats
[September 17, 2019]

<Department of Medical Biotechnology Professor Jin Joon-oh’s research team that developed new technologies that can be applied in immunotherapy of cancer through international joint research>
(left to right: YU Graduate School of Medical Biotechnology master’s degree course Park Hae-bin and Professor Jin Joon-oh)

 

 

The YU Department of Medical Biotechnology Professor Jin Joon-oh’s (39) research team developed new technologies that can be applied in immunotherapy of cancer through an international joint research project.

  Li Xu, a master’s degree student at Fudan University, and Park Hae-bin (24, 1st term in master’s degree course) of the YU Graduate School of Medical Biotechnology participated as the co-primary author and Professor Jin participated as the corresponding author. The study was published in the August 2019 issue of the world’s most authoritative academic journal in the immunotherapy of cancer sector, <Journal for Immunotherapy of Cancer, (impact factor (IF) = 8.68)>.

 

Professor Jin’s research team developed a ‘immuno-photothermy treatment liposome’ by adding immuno-activators and photothermy agents in liposome (phospholipid double layer structure with space inside that can be used for transporting materials, and is used as an antibiotic or drug delivery vehicle of anti-cancer drugs for treating cancer). The research team proved to noy only treat primary cancer in lab rats, but also that it could remove cancer that spread to other areas.
 
  Professor Jin said, “By mixing antigens of cancer cells through photothermy treatment and immuno-fortifiers secreted from liposomes, we induced cancer antigen-specific immuno-activity. Through this, we confirmed in our research that metastasis cancer was also removed.” He added, “This study will make immunotherapy of cancer possible using antigens created when cancer cells die.”
  Professor Jin who led the research team has published 32 research papers over the past five years based on this research for developing new immuno-supplements to develop cancer medicine as well as on developing infectious disease treatment. The studies of Professor Jin were published in world-acclaimed academic journals such as Biometerials, Nanoscale, and Frontiers in Immunology, thus receiving international recognition for his research achievements.